1. Home
  2. DKL vs XENE Comparison

DKL vs XENE Comparison

Compare DKL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DKL
  • XENE
  • Stock Information
  • Founded
  • DKL 2012
  • XENE 1996
  • Country
  • DKL United States
  • XENE Canada
  • Employees
  • DKL N/A
  • XENE N/A
  • Industry
  • DKL Natural Gas Distribution
  • XENE Biotechnology: Pharmaceutical Preparations
  • Sector
  • DKL Energy
  • XENE Health Care
  • Exchange
  • DKL Nasdaq
  • XENE Nasdaq
  • Market Cap
  • DKL 2.3B
  • XENE 2.4B
  • IPO Year
  • DKL N/A
  • XENE 2014
  • Fundamental
  • Price
  • DKL $43.74
  • XENE $33.18
  • Analyst Decision
  • DKL Buy
  • XENE Strong Buy
  • Analyst Count
  • DKL 4
  • XENE 11
  • Target Price
  • DKL $44.25
  • XENE $54.82
  • AVG Volume (30 Days)
  • DKL 96.4K
  • XENE 1.5M
  • Earning Date
  • DKL 08-05-2025
  • XENE 08-07-2025
  • Dividend Yield
  • DKL 10.15%
  • XENE N/A
  • EPS Growth
  • DKL 7.97
  • XENE N/A
  • EPS
  • DKL 2.98
  • XENE N/A
  • Revenue
  • DKL $938,491,000.00
  • XENE $7,500,000.00
  • Revenue This Year
  • DKL $21.19
  • XENE N/A
  • Revenue Next Year
  • DKL N/A
  • XENE $253.71
  • P/E Ratio
  • DKL $14.67
  • XENE N/A
  • Revenue Growth
  • DKL N/A
  • XENE N/A
  • 52 Week Low
  • DKL $34.59
  • XENE $26.74
  • 52 Week High
  • DKL $45.71
  • XENE $46.00
  • Technical
  • Relative Strength Index (RSI)
  • DKL 61.82
  • XENE 57.79
  • Support Level
  • DKL $42.29
  • XENE $31.09
  • Resistance Level
  • DKL $43.83
  • XENE $32.99
  • Average True Range (ATR)
  • DKL 0.91
  • XENE 1.21
  • MACD
  • DKL -0.05
  • XENE 0.20
  • Stochastic Oscillator
  • DKL 81.31
  • XENE 79.20

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Share on Social Networks: